A 7-year-old intact female Cavalier King Charles Spaniel ...

Thank you for reaching out about this Cavalier King Charles Spaniel. This is a classic presentation for myxomatous mitral valve disease (MMVD), and your detailed history and echocardiographic findings are excellent.

Based on the ACVIM consensus guidelines for MMVD, this patient is classified as Stage B2. Let me explain why:

Stage B1 vs. B2 Distinction: Stage B1 refers to dogs with structural heart disease (a murmur and/or echo changes) but without hemodynamically significant cardiac remodeling. Stage B2, on the other hand, identifies dogs with structural disease and significant cardiac enlargement, putting them at higher risk for progression to congestive heart failure (CHF). The key is the presence of specific echo criteria for chamber enlargement.

Patient's Echocardiographic Findings:

* LA:Ao ratio 1.7: This value is greater than or equal to 1.6, which is a primary criterion for defining significant left atrial enlargement in the context of MMVD.
LVIDdN 1.5: This value is less than 1.7, meaning there isn't significant left ventricular dilation by this specific criterion. However, only one* of the major criteria for chamber enlargement is needed to classify a patient as Stage B2.

Since your patient has an LA:Ao ratio of 1.7, which meets the threshold for significant left atrial enlargement, she falls squarely into ACVIM Stage B2.

Initiation of Pimobendan:

The landmark EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly caused by preclinical mitral valve disease) trial demonstrated a significant benefit of starting pimobendan in dogs with Stage B2 MMVD. The study showed that pimobendan delayed the onset of clinical signs of congestive heart failure by approximately 15 months and prolonged survival.

Therefore, based on these robust, evidence-based guidelines, pimobendan should be initiated now for this asymptomatic Cavalier King Charles Spaniel.

The recommended dose for pimobendan in dogs is 0.25-0.3 mg/kg PO Every 12 hours. It is crucial that pimobendan is administered on an empty stomach, ideally one hour before feeding, as food can significantly reduce its absorption by about 30%.

Important Considerations:

No Furosemide: I want to emphasize that while this dog has heart disease, she does not* have heart failure (she is asymptomatic, and you've confirmed no evidence of CHF). Therefore, furosemide is not indicated at this stage and should be strictly avoided. Starting a diuretic in a preclinical patient can lead to dehydration, azotemia, and activation of the renin-angiotensin-aldosterone system without providing any benefit.
* Monitoring Sleeping Respiratory Rate (SRR): This is the single most important monitoring tool for owners at home. Please instruct the owner to count their dog's sleeping respiratory rate daily. A normal SRR is typically less than 30 breaths per minute. Any sustained increase warrants immediate re-evaluation, as it can be the earliest sign of impending congestive heart failure.
* Re-evaluation: I would recommend re-evaluating this patient with an echocardiogram every 6-12 months to monitor disease progression.

In summary, your patient is a prime candidate for pimobendan initiation to delay the progression of her MMVD to clinical heart failure. This proactive approach, guided by strong evidence, aims to extend her quality of life significantly.